

# ProteoTuner™ Systems User Manual



PT4039-1 (PR8Z2655)  
Catalog Nos. 632167, 632168,  
632171, 632172, 632173, 632175,  
632190, 632191, 632192 & 632196  
Published 15 January 2009

## Table of Contents

|  |           |
|--|-----------|
| <b>I. Introduction.....</b>  | <b>3</b>  |
| <b>II. List of Components .....</b>  | <b>5</b>  |
| <b>III. Additional Materials Required .....</b>  | <b>6</b>  |
| A. Mammalian Cell Culture Supplies .....   | 6         |
| B. Antibiotics for Clonal Selection .....  | 6         |
| C. Additional Materials for Retro-X™ ProteoTuner Systems .....                               | 6         |
| D. Additional Materials for Lenti-X™ ProteoTuner Systems .....                               | 6         |
| <b>IV. ProteoTuner Assay Protocol Overview.....</b>  | <b>7</b>  |
| <b>V. ProteoTuner System Protocols .....</b>   | <b>8</b>  |
| A. Protocol: Propagating Plasmid ProteoTuner Vectors.....                                    | 8         |
| B. Protocol: Propagating Viral ProteoTuner Vectors.....                                      | 9         |
| C. Protocol: Optimizing Shield1 Concentration and Incubation Time .....                      | 10        |
| D. Protocol: DD-Protein Stabilization .....  | 11        |
| E. Protocol: DD-Protein Destabilization .....  | 11        |
| F. Protocol: Working with Stable Cell Lines Expressing a DD-Tagged Protein of Interest. .... | 12        |
| <b>VI. References .....</b>  | <b>12</b> |

### List of Figures

|   |   |
|---|---|
| Figure 1. Ligand-dependent, targeted, and reversible protein stabilization.....                 | 3 |
| Figure 2. Overview of the ProteoTuner protein stabilization and destabilization protocols ..... | 7 |

### List of Tables

|   |   |
|---|---|
| Table I: ProteoTuner Technology is Applicable to a Wide Variety of Cell Types & Organisms ..... | 4 |
| Table II: Characteristics of the ProteoTuner Systems.....                                       | 4 |

| Contact Us For Assistance           |                                     |
|-------------------------------------|-------------------------------------|
| Customer Service/Ordering:          | Technical Support:                  |
| Telephone: 800.662.2566 (toll-free) | Telephone: 800.662.2566 (toll-free) |
| Fax: 800.424.1350 (toll-free)       | Fax: 650.424.1064                   |
| Web: www.clontech.com               | Web: www.clontech.com               |
| E-mail: orders@clontech.com         | E-mail: tech@clontech.com           |


## I. Introduction

Analyzing protein function is a key focus in discovery-based cell biology research. The ProteoTuner technology, developed by Wandless and colleagues (Banaszynski *et al.*, 2006), allows you to directly investigate the function of a specific protein of interest—by directly manipulating the level of the protein itself. This fast regulation occurs directly at the protein level, rather than at the mRNA or promoter induction level, and enables you to control the quantity of a specific protein in the cell, in as little as 15 to 30 minutes.

This revolutionary method takes advantage of ligand-dependent, tunable stabilization/destabilization of the protein of interest. It is based on a 12 kDa mutant of the FKBP protein (the destabilization domain, or DD) that can be expressed as a tag on your protein of interest. In the presence of the small (750 Da), membrane-permeant, stabilizing ligand Shield1, the DD-tagged protein of interest is stabilized (protected from proteasomal degradation) and accumulates inside the cell (Figure 1). Ligand-dependent stabilization occurs very quickly: DD fusion proteins have been shown to accumulate to detectable levels just 15–30 minutes after the addition of Shield1 (Banaszynski *et al.*, 2006).

The ProteoTuner method is not restricted to protein *stabilization*—it can also be used to *destabilize* the DD-tagged protein when you culture your cells in medium without Shield1, allowing proteasomal degradation of the DD-protein (Figure 1). This makes it possible to “tune” the amount of stabilized DD-tagged protein present in the cell by titrating the amount of Shield1 in the culture medium, and to repeatedly stabilize and destabilize the protein of interest using the same set of cells.

**NOTE:** To be degraded effectively, the DD fusion protein needs to have access to the proteasomes within the cell. Regions of the cell that do not have access to the proteasomes (e.g., the lumen of the ER) will not allow DD-tagged protein degradation.



**Figure 1. Ligand-dependent, targeted, and reversible protein stabilization.** A small destabilization domain (DD; grey) is fused to a target protein of interest. The small membrane-permeable ligand Shield1 (black) binds to the DD and protects it from proteasomal degradation. Removal of Shield1, however, causes rapid degradation of the entire fusion protein. The default pathway for the ProteoTuner systems is degradation of the DD-tagged protein, unless Shield1 is present to stabilize it.

## I. Introduction continued

This technology has been used successfully in a variety of applications and organisms (Table I).

| Table I: ProteoTuner Technology is Applicable to a Wide Variety of Cell Types & Organisms |   |                                  |
|---|---|----------------------------------|
| Protein   | Organism/Cell Type                                | Reference                        |
| SIK1 (salt-inducible kinase)  | Mouse myocytes                                    | Berdeaux <i>et al.</i> , 2007    |
| Rab11a (a small GTP binding protein; dominant negative version)                           | <i>Toxoplasma gondii</i>                          | Herm-Götz <i>et al.</i> , 2007   |
| Falcipain-2   | <i>Plasmodium falciparum</i>                      | Armstrong <i>et al.</i> , 2007   |
| IL2   | HCT116 colon cancer line (xenografted into mouse) | Banaszynski <i>et al.</i> , 2008 |
| TNF- $\alpha$   | Mouse   |                                  |
| RhoA; Cdc42   | NIH3T3, HEK 293T, HeLa, and COS-1 cells           | Banaszynski <i>et al.</i> , 2006 |
| Membrane protein CD8 $\alpha$   | NIH 3T3 cells                                     |                                  |
| Cyclin B1   | HeLa  | Chu <i>et al.</i> 2008           |
| TRPV5 (membrane ion channel)  | HEK 293   | Schoeber <i>et al.</i> , 2008    |
| GPI-anchored protein  |   |                                  |
| MHC class I   |   |                                  |
|   | <i>Xenopus</i>                                    |                                  |
|   | Zebrafish   |                                  |

Several systems are available: with either conventional plasmid or viral vectors, and with or without a Living Colors® Fluorescent Protein marker for transfection. Some systems also include a fluorescent protein reporter, or a tag for ProLabel™ quantitation (Table II).

| Table II: Characteristics of the ProteoTuner Systems |                               |                |                        |                        |
|--|-------------------------------|----------------|------------------------|------------------------|
| System   | Conventional Plasmid Delivery | Viral Delivery | Antibiotic Resistance* | Fluorescent Protein    |
| ProteoTuner™ System                                  | Yes                           | No             | G418                   | No                     |
| ProteoTuner™ IRES2 System                            | Yes                           | No             | G418                   | (IRES2) AcGFP1 marker  |
| Retro-X™ ProteoTuner™ System                         | Yes                           | Retroviral     | (IRES) Puromycin       | No                     |
| Retro-X™ ProteoTuner™ IRES System                    | Yes                           | Retroviral     | No                     | (IRES) ZsGreen1 marker |
| Lenti-X™ ProteoTuner™ System                         | Yes                           | Lentiviral     | (IRES) Puromycin       | No                     |
| Lenti-X™ ProteoTuner™ Green System                   | Yes                           | Lentiviral     | No                     | (IRES) ZsGreen1 marker |
| DD-tdTomato Reporter System                          | Yes                           | No             | G418                   | tdTomato reporter      |
| DD-AmCyan1 Reporter System                           | Yes                           | No             | G418                   | AmCyan1 reporter       |
| DD-ZsGreen1 Reporter System                          | Yes                           | No             | G418                   | ZsGreen1 reporter      |
| ProteoTuner™ Quantitation System                     | Yes                           | No             | G418                   | No                     |

\* In mammalian cells.

## II. List of Components

Store Shield1 and all plasmids at –20°C.

### **ProteoTuner System (Cat. No. 632172)**

- 20 µg pPTuner Vector (Cat. No. 632170; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **ProteoTuner IRES2 System (Cat. No. 632168)**

- 20 µg pPTuner IRES2 Vector (Cat. No. 631036; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **Retro-X ProteoTuner System (Cat. No. 632171)**

- 20 µg pRetroX-PTuner Vector (Cat. No. 632169; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **Retro-X ProteoTuner IRES System (Cat. No. 632167)**

- 20 µg pRetroX-PTuner IRES Vector (Cat. No. 631035; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **Lenti-X ProteoTuner System (Cat. No. 632173)**

- 20 µg pLVX-PTuner Vector (Cat. No. 632174; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **Lenti-X ProteoTuner System Green (Cat. No. 632175)**

- 20 µg pLVX-PTuner Green Vector (Cat. No. 632176; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **DD-tdTomato Reporter System (Cat. No. 632190)**

- 20 µg pDD-tdTomato Reporter (Cat. No. 632193; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **DD-AmCyan1 Reporter System (Cat. No. 632191)**

- 20 µg pDD-AmCyan1 Reporter (Cat. No. 632194; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **DD-ZsGreen1 Reporter System (Cat. No. 632192)**

- 20 µg pDD-ZsGreen1 Reporter (Cat. No. 632195; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)

### **ProteoTuner Quantitation System (Cat. No. 632196)**

- 20 µg pPTuner Q Vector (Cat. No. 632197; not sold separately)
- 60 µl Shield1 (60 µl; Cat. No. 631037)
- 1 each ProLabel Detection Kit II (Cat. No. 631629)

### **Shield1**

- 60 µl Shield1 (Cat. No. 631037)
- 200 µl Shield1 (Cat. No. 631038)
- 500 µl Shield1 (Cat. No. 632189)

### III. Additional Materials Required

#### A. Mammalian Cell Culture Supplies

- Tissue culture plates or flasks
- Cell culture media
- Trypsin-EDTA (Trypsin; Sigma, Cat. No. T3924)
- Dulbecco's phosphate buffered saline (DPBS; VWR, Cat. No. 82020-066 or Sigma, Cat. No. D8662)
- Cell Freezing Medium, with or without DMSO (Sigma, Cat. No. C6164 or C6039)
- Tet System Approved Fetal Bovine Serum (FBS; Clontech, Cat. Nos. 631101, 631105, 631106 & 631107)

#### B. Antibiotics for Clonal Selection

Prior to using antibiotics to select transduced cells, determine the optimal selection concentration for each cell type.

- **G418** is available from Clontech (Cat. No. 631307).  
Note that the effective weight is about 0.7 g per gram of powder. Make a 10 mg/ml stock solution by dissolving 1 g of powder in approximately 70 ml of DMEM or  $\alpha$ -MEM (without supplements). Filter sterilize and store at 4°C.
  - Recommended working concentration range: 50–800  $\mu$ g/ml
  - Maintenance of stable cell lines: 100  $\mu$ g/ml
  - Selection (e.g., HEK 293, HeLa or CHO cells): 400–500  $\mu$ g/ml
- **Puromycin** is available from Clontech (Cat. Nos. 631305 & 631306)
  - Recommended working concentration range for viral systems: 1–2  $\mu$ g/ml

#### C. Additional Materials for Retro-X™ ProteoTuner Systems

- Retro-X Universal Packaging System (Cat. No. 631530)  
**NOTE:** Please refer to the Retroviral Gene Transfer and Expression User Manual (PT3132-1, available at <http://www.clontech.com/support/manuals.asp>) for a complete list of materials required.
- Retro-X qRT-PCR Titration Kit (Cat. No. 631451)  
**NOTE:** Please refer to the Retro-X qRT-PCR Titration Kit User Manual (PT3952-1, available at <http://www.clontech.com/support/manuals.asp>) for a complete list of materials required.

#### D. Additional Materials for Lenti-X™ ProteoTuner Systems

- Lenti-X HT Packaging System (Cat. Nos. 632160 & 632161)  
**NOTE:** Please refer to the Lenti-X Lentiviral Expression Systems User Manual (PT3983-1, available at <http://www.clontech.com/support/manuals.asp>) for a complete list of materials required.
- Lenti-X 293T Cell Line (Cat. No. 632180)  
Alternatively, you can use the HEK 293T cell line; American Type Culture Collection HEK 293T/17 (ATCC No. CRL-11268™)
- Tet System Approved Fetal Bovine Serum (Cat. Nos. 631101, 631105, 631106 & 631107)
- Lenti-X qRT-PCR Titration Kit (Cat. No. 632165)  
**NOTE:** Please refer to the Lenti-X qRT-PCR Titration Kit User Manual (PT4006-1, available at <http://www.clontech.com/support/manuals.asp>) for a complete list of materials required.

## IV. ProteoTuner Assay Protocol Overview

### Protein Stabilization

In order to stabilize your protein of interest, you can add the stabilizing ligand, Shield1, to one of two parallel cell cultures which were previously untreated with Shield1 (Figure 2, Panel A). The other culture will be continuously cultured in the absence of Shield1 as a negative control.

The added Shield1 will protect your DD-tagged protein of interest from proteasomal degradation, causing a dramatic increase in its level in the cell. Stabilization has been reported in as little as 15–30 minutes (Banaszynski *et al.*, 2006) but we recommend performing a time course experiment in order to determine the stabilization rate after addition of Shield1 for your protein of interest.


At different time points, analyze the treated and control cells using your method of choice (e.g., Western blot or phenotypic analysis), depending on your experimental goals.

### Protein Destabilization

The default pathway of the ProteoTuner Systems is rapid destabilization and degradation of the DD-tagged protein (Figure 1). In order to destabilize/degrade your protein of interest that has previously been stabilized, split cells which were previously treated with Shield1 into two parallel cultures (Figure 2, Panel B). One culture will continue to be cultured in the presence of Shield1 as a positive control, and the second (experimental) culture will be cultured without the stabilizing ligand, Shield1.

In the absence of Shield1, the DD-tagged protein of interest will be degraded rapidly. Degradation half lives of one to two hours have been reported (Banaszynski *et al.*, 2006), but we recommend performing a time course experiment in order to assess the rate of degradation of your protein of interest.

At different time points, analyze the treated and control cells using your method of choice (e.g., Western blot or phenotypic analysis), depending on your experimental goals.



**Figure 2. Overview of the ProteoTuner protein stabilization and destabilization protocols.** Both protocols are based on Shield1's ability to reversibly stabilize DD-tagged fusion proteins (see Figure 1). **Panel A.** In order to observe the effects of stabilizing your protein of interest (POI), begin with cells cultured in medium that does not contain Shield 1. Then add Shield1, and as your DD-protein of interest is stabilized, perform your experimental analysis at defined time points in order to determine the protein's effects. **Panel B.** To observe the effects of the loss of your protein of interest, begin with cells cultured in medium that contains Shield1, and then split the cells into medium without Shield1 to destabilize your DD-protein of interest. Then perform your experimental analysis at defined time points in order to determine the effects of the loss of your protein of interest.

## V. ProteoTuner System Protocols

**PLEASE READ THE ENTIRE PROTOCOL BEFORE STARTING.**



Protocol

### A. Protocol: Propagating Plasmid ProteoTuner Vectors

The ProteoTuner IRES2 System and ProteoTuner System include plasmid-based vectors. Each vector includes either a Living Colors® Fluorescent Protein or an antibiotic selection marker for transfection and transduction (Table II).

**Selection by fluorescent protein:** The **ProteoTuner IRES2 System** contains an internal ribosome entry sequence (IRES) following the DD-tagged gene of interest. This allows AcGFP1 to be translated independently of the DD-tagged protein. AcGFP1 expression is *not* regulated by the stabilizing ligand, Shield1. Therefore, detection of green fluorescence in a cell by either fluorescence microscopy or flow cytometry analysis indicates that the cell has been transfected and is expressing your DD-tagged protein of interest.

**Antibiotic selection:** If required, stable transfectants can be selected using G418 (Cat. Nos. 631305 & 631306). Please see Part III.B, Additional Materials Required, for more information about antibiotic selection.

1. To ensure that you have a renewable source of plasmid DNA, transform the plasmid vector provided with your system into a suitable *E. coli* host strain (e.g., DH5α). See the enclosed Vector Information Packet for further DNA propagation details.
2. To generate plasmid DNA for cloning purposes, use a suitable **NucleoBond®** or **NucleoSpin Kit®**. NucleoBond Xtra Kits provide the fastest and most convenient means available to achieve high yields of transfection-quality plasmid DNA. See [www.clontech.com](http://www.clontech.com) for available kits and options.
3. Using standard cloning techniques, insert your cDNA into the multiple cloning site (MCS) of the vector, in-frame with the DD domain. Your gene of interest must contain its own stop codon. The resulting construct can then be transfected into the cells of interest using your method of choice. We recommend using In-Fusion™ PCR Cloning Kits to perform your cloning.

**NOTE:** For more information on Living Colors Fluorescent Proteins, please refer to our website, <http://www.clontech.com/colors>



Website



## V. ProteoTuner System Protocols continued



### B. Protocol: Propagating Viral ProteoTuner Vectors

We offer both retroviral and lentiviral delivery of ProteoTuner technology. Each vector includes either a Living Colors® Fluorescent Protein or an antibiotic selection marker for transfection and transduction (Table II).



**Selection by fluorescent protein:** The **Retro-X ProteoTuner IRES System** and the **Lenti-X ProteoTuner Green System** each include a vector which contains an IRES sequence following the DD-tagged gene of interest. This allows ZsGreen1 to be translated independently of the DD-tagged protein. ZsGreen1 expression is not regulated by the stabilizing ligand, Shield1. The detection of green fluorescence in a cell by either fluorescence microscopy or flow cytometry analysis indicates that the cell has been transduced and is expressing your DD-tagged protein of interest.

**NOTE:** For information on Living Colors Fluorescent Proteins, please visit <http://www.clontech.com/colors>

**Antibiotic selection:** The **Retro-X ProteoTuner System** and the **Lenti-X ProteoTuner System** each include a vector which contains an IRES sequence following the DD-tagged gene of interest. This allows the antibiotic resistance gene for puromycin to be translated independently of the DD-tagged protein. This can be used to establish stable cell lines by selection with G418 (Cat. Nos. 631305 & 631306). Please see Part III.B, Additional Materials Required, for more information about antibiotic selection.

1. To ensure that you have a renewable source of plasmid DNA, transform the vector provided with your system into a suitable *E. coli* host strain which can prevent recombination between homologous LTRs (e. g., Supercharge EZ10 Electrocompetent Cells, Cat. No. 636756). See the enclosed Vector Information Packet for further DNA propagation details.
2. To generate the construct of interest, insert your gene of interest into the multiple cloning site (MCS) in-frame with the DD domain, using standard cloning techniques. Your gene of interest must contain its own stop codon but no poly A site. We recommend using In-Fusion PCR Cloning Kits to perform your cloning.
3. Produce your retrovirus or lentivirus:
  - **To generate retrovirus** from your pRetro-X-PTuner construct, use the Retro-X Universal Packaging System (Cat. No. 631530) according to the Retroviral Gene Transfer and Expression User Manual (PT3132-1). See the Vector Information Packet included with your pRetro-X-PTuner vector for further DNA propagation details. You can perform this initial transfection by your method of choice. We recommend using the CalPhos™ Mammalian Transfection Kit (Cat. No. 631312).

**NOTE:** The Retroviral Gene Transfer and Expression User Manual (PT3132-1) is available at <http://www.clontech.com/support/manuals.asp>

  - **To generate lentivirus** from your pLVX-PTuner construct, use the Lenti-X HT Packaging System (Cat. Nos. 632160 & 632161) to cotransfect your construct into Lenti-X 293T Cells (Cat. No. 632180) according to the Lenti-X Lentiviral Expression Systems User Manual (PT3983-1). See the Vector Information Packet included with your pLVX-PTuner vector for further DNA propagation details.

**NOTE:** The Lenti-X Lentiviral Expression Systems User Manual (PT3983-1) is available at <http://www.clontech.com/support/manuals.asp>
4. Collect the viral supernatant 48–72 hours posttransfection. At this point you must determine your viral titer and infect your desired target cells.
  - **For retroviruses**, we recommend using the Retro-X qRT-PCR Titration Kit (Cat. No. 631451) to determine your viral titer.
  - **For lentiviruses**, we recommend using the Lenti-X qRT-PCR Titration Kit (Cat. No. 632165) to determine your viral titer.



## V. ProteoTuner System Protocols continued



### C. Protocol: Optimizing Shield1 Concentration and Incubation Time

Before you begin, transfect (or infect) your DD construct of interest into your cells of interest, using your method of choice (See Protocols A–B, above).

1. 12–24 hours posttransfection (for plasmid vectors) or postinfection (for viral vectors), split the cells into at least two parallel cultures (a plate treated with Shield1 and an untreated negative control).

Dilute the amount of Shield1 needed for your experiment.

Shield1 is provided as a 0.5 mM stock solution. It needs to be diluted to the final concentration in warm (37°C) culture medium, and mixed well. We recommend beginning with a range between 50–1,000 nM for the final concentration of Shield1.

You can dilute the Shield1 stock solution with culture medium that has already been used to culture the cells, or with fresh culture medium:

- Collect the media supernatant from your cell culture into a clean and sterile container and add the appropriate amount of Shield1 to reach the appropriate final concentration. After mixing, add the medium containing Shield1 back into the plate, or
- Warm up the appropriate volume of fresh culture media needed for your experiment to ~37°C. Then add the appropriate volume of Shield1 stock solution, to obtain the final concentration of Shield1 to be used in the experiment.

Example: Preparing 10 ml of culture media containing 500 nM Shield1.

|       |  |
|-------|--|
| 10 ml | Warm culture medium (37°C; either collected from your tissue culture plate, or fresh media) in a sterile tube. |
| 10 µl | 0.5 mM stock solution  |
| 10 ml | 500 nM Shield1 (final concentration)   |

2. Optimize the Shield1 concentration:
  - a. The final concentration of Shield1 used in the experiment may vary, depending on the type of cells used as well as your particular DD-tagged protein of interest. Because the system is tunable, you can regulate or “tune” the amount of stabilized DD-fusion protein of interest in your cells by adding either more or less of the stabilizing ligand Shield1 to the culture media.
  - b. We suggest testing various Shield1 concentrations within the recommended range (50–1,000 nM Shield1 in your culture medium) in order to determine the concentration that best fits your experimental needs.
4. Optimize the Shield1 incubation time.
 

Your protein of interest may be detectable as early as 15–30 minutes after addition of the stabilizing ligand, Shield1 (Banaszynski *et al.*, 2006). We recommend performing a time course experiment in order to determine the optimal incubation time with Shield1.

## V. ProteoTuner System Protocols continued



### Protocol

#### D. Protocol: DD-Protein Stabilization

Before you begin, transfect (or infect) your DD construct of interest into your cells of interest, using your method of choice (See Protocols A–B, above).

1. 12–24 hours posttransfection (for plasmid vectors) or postinfection (for viral vectors), split the cells into at least two parallel cultures (an experimental plate which will be treated with Shield1, and an untreated negative control).

**For cells growing in suspension,** collect your cells and distribute the cell suspension evenly into at least two tubes (the number of tubes depends on the number of samples you would like to collect). Centrifuge the cells for 5 minutes at  $\leq 1,000$  RPM, and remove the media.

2. Dilute the Shield1 to the optimal concentration determined in Protocol C. We recommended final concentrations of  $\sim 50$ – $1,000$  nM Shield1 in the cell culture medium.
3. Once the cells are attached to each plate or resuspended in each tube, remove the culture medium and replace with warm media with or without Shield1, respectively.

The added Shield1 will protect your DD-tagged protein of interest from proteasomal degradation, causing a rapid increase in its level in the cell.

4. Collect cells at specific time points after treating with Shield1 (defined by your needs) in order to analyze and compare cells with and without the stabilized DD fusion protein of interest.



### Protocol

#### E. Protocol: DD-Protein Destabilization

Before you begin, transfect (or infect) your DD construct of interest into your cells of interest, using your method of choice (See Protocols A–B, above). Culture your cells in medium containing Shield1 at the optimal concentration determined in Protocol C, to stabilize your protein of interest.

1. 12–24 hours posttransfection (for plasmid vectors) or postinfection (for viral vectors), split the cells into at least two parallel cultures (an experimental plate treated with Shield1 and an untreated negative control).
2. Rinse the cells with warm Dulbecco's Phosphate Buffered Saline (TC grade).
3. Detach the cells by your method of choice (trypsin, cell dissociation buffer, etc.).

**For cells growing in suspension,** collect your cells and distribute the cell suspension evenly in at least two tubes (the number of tubes depends on the number of samples you would like to collect). Centrifuge the cells for 5 minutes at  $\leq 1,000$  RPM and remove the media. Then resuspend the cell pellet in media with and without the appropriate concentration of Shield1 and culture for the appropriate amount of time determined by your needs. Proceed to step 6.

4. Split the cells into at least two new cell culture plates.
5. Culture the cells in one plate in the presence of Shield1 in the medium (positive control) and culture the second plate without Shield1.
6. Collect cells at specific time points (defined by your needs) after splitting and growing them in media with and without Shield1 in order to analyze and compare cells with and without the stabilized DD fusion protein of interest.

**NOTE:** To remove Shield1 without splitting the cell culture, wash cells three times with culture medium (without Shield1).



## V. ProteoTuner System Protocols continued



### F. Protocol: Working with Stable Cell Lines Expressing a DD-Tagged Protein of Interest

1. After establishing a stable cell line, you can culture your cells either in the absence or the presence of Shield1, depending on your experimental needs.
2. If you grow your cells in the absence of Shield1, your protein of interest will be destabilized and expressed only at a very low level in your stable cell line. Then Shield1 can be added to rapidly increase the amount of your protein of interest (Protocol D).
3. Maintenance in, or addition of Shield1 to a stable cell line will stabilize your protein of interest and quickly increase its level in the cell (Protocol E).

## VI. References

- Armstrong, C. M. & Goldberg, D. E. (2007) An FKBP destabilization domain modulates protein levels in *Plasmodium falciparum*. *Nature Meth.* **4**(12):1007–1009.
- Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G., & Wandless, T. J. (2006) A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. *Cell* **126**(5):995–1004.
- Banaszynski, L. A. & Wandless, T. J. (2006) Conditional control of protein function. *Chem. Biol.* **13**(1):11–21.
- Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J., & Thorne, S. H. (2008) Chemical control of protein stability and function in living mice. *Nature Med.* **14**(10):1123–1127.
- Berdeaux, R., Goebel, N., Banaszynski, L., Takemori, H., Wandless, T., Shelton, G. D., & Montminy, M. (2007) SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. *Nature Med.* **13**(5): 597–603.
- Grimley, J. S., Chen, D. A., Banaszynski, L. A., & Wandless, T. J. (2008) Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains. *Bioorg. Med. Chem. Lett.* **18**(2):759–761.
- Herm-Götz, A., Agop-Nersesian, C., Münter, S., Grimley, J. S., Wandless, T. J., Frischknecht, F., & Meissner, M. (2007) Rapid control of protein level in the apicomplexan *Toxoplasma gondii*. *Nature Meth.* **4**(12):1003–1005.
- Maynard-Smith, L. A., Chen, L., Banaszynski, L. A., Ooi, A. G. L., & Wandless, T. J. (2007) A Directed Approach for Engineering Conditional Protein Stability Using Biologically Silent Small Molecules *J. Biol. Chem.* **282**(34):24866–24872.
- Schoeber, J. P., van de Graaf, S. F., Lee, K. P., Wittgen, H. G., Hoenderop, J. G., & Bindels, R. J. (2008) Conditional fast expression and function of multimeric TRPV5 channels using Shield-1. *Am J Physiol Renal Physiol*. E-pub ahead of print.

#### Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

#### CMV Promoter:

The CMV promoter is covered under U.S. Patent Nos. 5,168,062, and 5,385,839 assigned to the University of Iowa Research Foundation.

#### cPPT Element:

This product and its use are the subject of U.S. Pat. No. 6,682,907 and pending foreign patent applications licensed to Clontech. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Clontech is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 ([www.pasteur.fr](http://www.pasteur.fr)).

**Notice to Purchaser, continued**

**DsRed-Express & DsRed-Express2:** Patent Pending.

**Fruit Fluorescent Protein Products pmBanana, pmCherry, pmOrange, pmPlum, pmRaspberry, pmStrawberry, ptdTomato and their variants:** Not-For-Profit Entities: Orders may be placed in the normal manner by contacting your local representative or Clontech Customer Service at 650.919.7300. At its discretion, Clontech grants Not-For-Profit Entities a non-exclusive, personal, limited license to use this product for non-commercial life science research use only. Such license specifically excludes the right to sell or otherwise transfer this product, its components or derivatives thereof to third parties. No modifications to the protein coding sequence may be made without express written permission from Clontech. Any other use of this product requires a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com). For-Profit Entities wishing to use this product are required to obtain a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com).

**Lentiviral Expression Products:**

Portions of this product are covered by several patent applications owned by, or licensed to, Open Biosystems, Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product of any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics.

This product is sold pursuant to a license from Open Biosystems, Inc., and Open Biosystems, Inc. reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact Open Biosystems' licensing officer at 256.319.1462.

**Living Colors® Products AcGFP1, DsRed, HcRed, AsRed, AmCyan, ZsGreen, ZsYellow and their variants:**

Not-For-Profit Entities: Orders may be placed in the normal manner by contacting your local representative or Clontech Customer Service at 650.919.7300. At its discretion, Clontech grants Not-For-Profit Entities a non-exclusive, personal, limited license to use this product for non-commercial life science research use only. Such license specifically excludes the right to sell or otherwise transfer this product, its components or derivatives thereof to third parties. No modifications to the protein coding sequence may be made without express written permission from Clontech. Any other use of this product requires a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com).

For-Profit Entities wishing to use this product are required to obtain a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at [licensing@clontech.com](mailto:licensing@clontech.com).

**ProLabel™ Products:** This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Clontech Laboratories, Inc.

**ProteoTuner™ Protein Stabilization/Destabilization Products:** Patent Pending.

**WPRE Technology:**

Clontech has a license to sell products containing the WPRE, under the terms described below. Any use of WPRE outside of Clontech's Product or the Product's intended use, requires a license as detailed below. Before using the Product containing WPRE, please read the following license agreement. If you do not agree to be bound by its terms, contact Clontech within 10 days for authorization to return the unused Product containing WPRE and to receive a full credit.

**Patents:** The WPRE technology is covered by patents issued to The Salk Institute for Biological Studies.

**Individual License Agreement:** Clontech grants you a non-exclusive license to use the enclosed Product containing WPRE in its entirety for its intended use. The Product containing WPRE is being transferred to you in furtherance of, and reliance on, such license. Any use of WPRE outside of Clontech's Product or the Product's intended use, requires a license from the Salk Institute for Biological Studies.

**Termination of License:** This license agreement is effective until terminated. You may terminate it at any time by destroying all Products containing WPRE in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Products containing WPRE in your control, and so notify Clontech in writing. This License shall be governed in its interpretation and enforcement by the laws of the State of California. Contact for WPRE Licensing:

The Salk Institute for Biological Studies  
10010 North Torrey Pines Road  
La Jolla, CA 92037  
Attn.: Office of Technology Management  
Phone: 858.453.4100 ext. 1275  
Fax: 858.546.8093

NucleoBond® and NucleoSpin® are registered trademarks of MACHERY-NAGEL GmbH & Co.

ProLabel™ is a trademark of DiscoverX, Inc.

Clontech, the Clontech Logo and all other trademarks are property of Clontech Laboratories, Inc., unless noted otherwise.

Clontech is a Takara Bio Company. ©2009 Clontech Laboratories, Inc.